GeneDx’s (WGS) “Sell (D)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d) rating on shares of GeneDx (NASDAQ:WGS) in a research report released on Wednesday,Weiss Ratings reports.

A number of other equities analysts also recently weighed in on WGS. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 2nd. Guggenheim restated a “buy” rating and set a $115.00 target price (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Piper Sandler boosted their target price on shares of GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Wall Street Zen upgraded shares of GeneDx from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, Wells Fargo & Company boosted their target price on shares of GeneDx from $78.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 30th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $104.13.

GeneDx Price Performance

NASDAQ WGS opened at $121.72 on Wednesday. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. GeneDx has a 12-month low of $54.14 and a 12-month high of $136.00. The company has a market capitalization of $3.50 billion, a PE ratio of 2,434.40 and a beta of 1.98. The firm’s 50 day moving average is $121.39 and its 200-day moving average is $95.23.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. Equities research analysts anticipate that GeneDx will post 0.97 earnings per share for the current fiscal year.

Insider Activity at GeneDx

In other news, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $452,840.16. Following the completion of the sale, the chief financial officer owned 8,755 shares of the company’s stock, valued at approximately $1,063,469.85. The trade was a 29.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jason Ryan sold 38,072 shares of the business’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the completion of the sale, the director directly owned 103,284 shares of the company’s stock, valued at approximately $13,148,053.20. The trade was a 26.93% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 556,371 shares of company stock valued at $67,489,314. 29.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently modified their holdings of WGS. T. Rowe Price Investment Management Inc. bought a new stake in shares of GeneDx in the first quarter valued at about $44,614,000. William Blair Investment Management LLC boosted its position in shares of GeneDx by 37.2% in the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock valued at $150,595,000 after acquiring an additional 442,414 shares during the period. Alliancebernstein L.P. boosted its position in shares of GeneDx by 3,054.5% in the first quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock valued at $38,694,000 after acquiring an additional 423,050 shares during the period. Jennison Associates LLC raised its stake in GeneDx by 6,163.1% in the second quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock valued at $36,730,000 after purchasing an additional 391,543 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in GeneDx by 164.8% in the second quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company’s stock valued at $54,388,000 after purchasing an additional 366,711 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.